Mahnaz Darvish-Damavandi
A5047306273- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Mathematical Biology Tumor Growth
- Gastric Cancer Management and Outcomes
- Health and Medical Research Impacts
- SARS-CoV-2 and COVID-19 Research
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Complement system in diseases
- Nanoplatforms for cancer theranostics
- Drug Transport and Resistance Mechanisms
- Nanoparticle-Based Drug Delivery
- Immune Cell Function and Interaction
- Biotin and Related Studies
- Angiogenesis and VEGF in Cancer
- Mitochondrial Function and Pathology
- Biochemical Acid Research Studies
- Biochemical and biochemical processes
- Inflammasome and immune disorders
- Neurological diseases and metabolism
- COVID-19 and healthcare impacts
- Helicobacter pylori-related gastroenterology studies
- Cancer Cells and Metastasis
University of Oxford
2020-2023
Wellcome/MRC Cambridge Stem Cell Institute
2020-2022
Nuffield Orthopaedic Centre
2021
University of Cambridge
2020
Institute of Cancer Research
2015-2019
National University of Singapore
2014-2016
Tehran University of Medical Sciences
2010
Cancer organoids to model therapy response are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches used predict drug responses clinic. They generated a live organoid biobank patients with metastatic gastrointestinal cancer who had previously been enrolled phase I or II clinical trials. This allowed authors compare how actually responded Encouragingly,...
Abstract Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting enzyme 2 (ACE2) 1 , could represent a new chemoprophylactic approach for COVID-19 that complements vaccination 2,3 . However, the mechanisms control expression of ACE2 remain unclear. Here we show farnesoid X receptor (FXR) is direct regulator transcription in several tissues affected COVID-19, including gastrointestinal and respiratory systems. We then use over-the-counter compound...
Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection patient progression. However, how to exploit the predictive power cfDNA as a liquid biopsy in clinic remains unclear. RAS pathway aberrations can be tracked monitor resistance anti-EGFR monoclonal antibodies patients with metastatic colorectal cancer. In this prospective phase II clinical trial single-agent cetuximab
Objective Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection. Design Patients RAS mutant mCRC biopsiable metastases were enrolled this phase II trial. Dynamic contrast-enhanced (DCE) MRI was acquired pretreatment at day 15 post-treatment. Median values volume transfer constant (K trans ), enhancing fraction (EF) their...
Abstract Purpose: Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. RAS status and tumor location (sidedness) predictive markers patients' response to anti-EGFR mAbs. Recently, low miR-31-3p expression levels have been correlated with clinical benefit from mAb cetuximab. Here, we aimed validate power a prospective cohort chemorefractory mCRC patients treated single-agent Experimental Design: was tested by situ hybridization (ISH) 91 pretreatment...
An immunosuppressive microenvironment causes poor tumor T cell infiltration and is associated with reduced patient overall survival in colorectal cancer. How to improve treatment responses these tumors still a challenge. Using an integrated screening approach identify cancer-specific vulnerabilities, we identified complement receptor C5aR1 as druggable target, which when inhibited improved radiotherapy, even displaying features CD8+ infiltration. While well-known for its role the immune...
Previous work utilizing proteomic and immunohistochemical analyses has identified that high levels of acid ceramidase (AC) expression confers a poorer response to neoadjuvant treatment in locally advanced rectal cancer. We aimed assess the radiosensitising effect biological pharmacological manipulation AC elucidate underlying mechanism. three colorectal cancer cell lines (HT29, HCT116 LIM1215) was achieved using siRNA plasmid overexpression. Carmofur novel small molecular inhibitor (LCL521)...
Propionic acidemia (PA) is a life-threatening disease caused by the deficiency of mitochondrial biotin-dependent enzyme known as propionyl coenzyme-A carboxylase (PCC). This responsible for degrading metabolic intermediate, (PP-CoA), derived from multiple pathways. Currently, except drastic surgical and dietary intervention that can only provide partial symptomatic relief, no other form therapeutic option available this genetic disorder. Here, we examine novel approach in protein delivery...
Propionyl coenzyme-A carboxylase (PCC) is a mitochondrial enzyme previously quantifiable only by radiometric assay. Herein, we report UPLC-MS/MS method as superior alternative for assaying PCC's activity. METHODOLOGY & RESULTS: For the development of method, mass spectra propionyl and methyl malonyl precursor ions, their full scan product ions were determined. MRM was used quantification analytes. The showed good linearity selectivity further bioanalytical study. developed capable rapidly...
Abstract Prevention of SARS-CoV-2 entry in cells through the modulation viral host receptors, such as ACE2, could represent a new therapeutic approach complementing vaccination. However, mechanisms controlling ACE2 expression remain elusive. Here, we identify farnesoid X receptor (FXR) direct regulator transcription multiple COVID19-affected tissues, including gastrointestinal and respiratory systems. We demonstrate that FXR antagonists, over-the-counter compound z-guggulsterone (ZGG)...
Abstract Background: AE-mABs (cetuximab and/or panitumumab) have been approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Indeed, previous studies identified mutations (MTs)/amplifications in RAS/RAF/MEK kinase pathway as main genetic events promoting primary and acquired resistance to these mABs. status is frequently established on archival material, tumour re-biopsy may not be always feasible. PROSPECT-C a prospective trial aiming define...
<h3>Introduction</h3> The management of COVID19 is complicated by vaccine availability, the modest efficacy existing treatments, and potential for viral resistance. Therefore, there a pressing need new prophylactic therapeutic agents. receptor ACE2 an ideal target as it required SARS-CoV-2 entry in host cells. Modifying expression could prevent infection and/or limit disease progression. Nevertheless, mechanisms controlling remain elusive. <h3>Aims</h3> To identify pathways transcriptional...
Abstract Background. Progressive accumulation of mutations in oncogenic and tumor suppressor pathways are associated with colorectal cancer (CRC). Mutations APC, KRAS p53 represent key drivers events CRC initiation progression simultaneously mutated about 30% CRC. Tumor derived Organoids (TDO) three-dimensional (3-D) structures composed cells that spatially organized like mini-guts a useful ex vivo tool to study intestinal physiology progression. Here, we investigated the progressive...
Abstract An immunosuppressive microenvironment causes poor tumour T-cell infiltration and is associated with reduced patient overall survival in colorectal cancer. How to improve treatment responses these tumours still a challenge. Using an integrated screening approach identify cancer-specific vulnerabilities, we complement receptor C5aR1 as druggable target which when inhibited improves radiotherapy even displaying features CD8+ infiltration. While well-known for its role the immune...
<p>Supplementary Figures and Tables</p>
<div>AbstractPurpose:<p>Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. <i>RAS</i> status and tumor location (sidedness) predictive markers patients' response to anti-EGFR mAbs. Recently, low miR-31-3p expression levels have been correlated with clinical benefit from mAb cetuximab. Here, we aimed validate power a prospective cohort chemorefractory mCRC patients treated single-agent mAbs.</p>Experimental...
<div>AbstractPurpose:<p>Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. <i>RAS</i> status and tumor location (sidedness) predictive markers patients' response to anti-EGFR mAbs. Recently, low miR-31-3p expression levels have been correlated with clinical benefit from mAb cetuximab. Here, we aimed validate power a prospective cohort chemorefractory mCRC patients treated single-agent mAbs.</p>Experimental...
<p>Supplementary Figures and Tables</p>
<p>Supplementary methods and Figures S1-S17</p>